Zeptronics Diagnostics COVID-19 Rapid Response Offers Unique
 Non-Invasive Testing and
Cellular-Level Results Unmatched Anywhere!

Zeptronics Diagnostics COVID-19 Rapid Response Testing and Results

The Global COVID-19 Diagnostic Testing Market is estimated to be valued at $44.4 billion US for the year 2020 owing to a rapid increase in the number of coronavirus cases across the globe, boosting demand for COVID-19 diagnostic tests. North America is dominating the COVID-19 Test Kits market in terms of revenue due to the high number of infected patients from novel coronavirus.

Zeptronic Diagnostics has developed a remarkable revolutionary diagnostic system that is going to change the way the world looks at medical testing.

Specifically, our product is a handheld probe device (both emitter and receiver) that features a patented proprietary cloud-based medical diagnostic technology that offers invasive-free diagnostic testing for many medical conditions, including SARS-CoV-2 infection (the virus that causes COVID-19).

Traditional Diagnostics vs. Zeptronic Diagnostics for COVID-19

Taking a look at the current state of medical diagnostics, we find that much of it is:

•       Costly, inefficient, and time-consuming

•       Mostly painful and invasive fluid collection and fluid administration

•       Purely speculative in the determination of disease or normal baseline spectrum

•       Often numerous tests to make a diagnosis

•       Often requires numerous trips to the doctor's office just to determine a diagnosis.

 With respect to COVID-19, confirmation of active SARS-CoV-2 infection (the virus that causes COVID-19) is currently being done via tests that use molecular “PCR” amplification and antigen-based lab technology. 

With Zeptronic Diagnostics, testing goes beyond the molecular to the cellular, all without

 Let’s compare Traditional vs. Zeptronic Diagnostics: